Seminar article
Radiation therapy for urologic malignancies in the elderly

https://doi.org/10.1016/j.urolonc.2009.07.019Get rights and content

Abstract

Radiotherapy is a commonly employed modality in the treatment of older men with urologic malignancies. The treatment recommendations should not be solely based on age even though optimal therapy for older patients continues to evolve. Radiotherapy is well tolerated by elderly prostate cancer patients and comparisons with other modalities should incorporate validated health-related quality of life measures, which is an important consideration in this age group. Due to lack of quality data, there is a need to optimize decision making process for older prostate cancer patients with more robust evidence-based measures. The new and emerging radiotherapeutic technologies are likely to benefit older patients with improvement in therapeutic ratio resulting from reduced dose delivery to normal tissues. The use of novel techniques, such as intensity modulated radiation therapy, image guidance and proton beam therapy, and their potential benefits for older population are discussed. This article also reviews the role of radiotherapy in older patients with other urologic malignancies, such as testicular tumor, bladder cancer, renal carcinoma, and penile cancer.

Introduction

Radiation therapy (RT) has a long history in the treatment of patients with urologic cancers, with the first patient treated not long after the discovery of X-rays over a century ago. Today, RT occupies an important therapeutic role in a wide variety of urologic malignancies, including prostate, bladder, and testicular cancers. In these patients, RT may be delivered either alone, as definitive therapy, or in combination with surgery and/or systemic therapies (chemotherapy, hormonal therapy).

RT is particularly common in the treatment of the elderly urologic cancer patient in whom surgery is precluded by either medical co-morbidities or disease extent. Moreover, it is commonly delivered in older patients to palliate symptoms when cure is no longer possible. The purpose of this article is to provide an overview of the use of RT in the elderly urologic cancer patient. Our focus will be on published clinical studies; however, potential uses of novel emerging radiation technologies in the older patient will also be highlighted.

Section snippets

Prostate cancer

Prostate cancer is the most common cancer diagnosed in older men [1]. Currently, prognosis and treatment decisions in these patients are based on risk stratification using variables, such as tumor stage, Gleason score, and serum prostate-specific antigen (PSA). There is considerable variation in the treatment approach to the older cancer patient due to multiple confounding factors, such as age, life expectancy, medical comorbidities, performance status, and importantly bias among physicians

Selection of radiation therapy

Age alone should not be used as the criteria for selecting appropriate therapy and treatment modality in prostate cancer patients. Since screening approaches and the treatment employed in the elderly remain controversial and debatable [6], outcomes based on quality of life have significant implications. Definitive RT and radical prostatectomy (RP) are the most commonly employed treatment options for localized prostate cancer. HRQOL measures have recently been reported using these two modalities

Combined radiation and androgen deprivation

The use of RT in combination with androgen deprivation for high risk prostate cancer patients is clearly supported by multiple randomized trials [21], [22]. However, several questions remain unanswered, including the optimum sequencing and duration of androgen deprivation. The rationale for combining hormone therapy and RT is a synergistic enhancement of radiation-induced cell killing, possibly through promotion of apoptosis and decrease of hypoxia. The target coverage with RT is also improved,

Brachytherapy

Brachytherapy involves the insertion of radioactive seeds into the prostate gland, thereby delivering high radiation doses within the target with a rapid dose fall-off of dose sparing surrounding critical organs, notably the rectum and bladder. Brachytherapy may be performed with a permanent seed implant using low dose rate sources (iodine-125 or palladium-103). Alternatively, the use of temporary high dose rate brachytherapy approaches has also been reported.

Brachytherapy offers several

Post-prostatectomy radiation therapy

While the proportion of older prostate cancer patients treated with definitive surgery is small, it is important to carefully evaluate the pathologic features following surgery, offering adjuvant RT to select patients with adverse factors. Multiple prospective, randomized trials have shown that adjuvant RT following RP improves progression-free survival in men with high risk features such as a positive margin, seminal vesicle involvement or extra-capsular extension [28], [29], [30]. Moreover,

Emerging technologies

Over the past 20 years, several novel RT technologies have been introduced, improving the quality and delivery of RT in prostate cancer patients. All have important implications for elderly patients. Perhaps the most important of these technologies is intensity-modulated RT (IMRT). IMRT is a sophisticated radiation delivery technique achieving high conformity using optimization software [33]. With IMRT, radiation dose is conformed to the shape of the target in three dimensions, thereby limiting

Palliation

RT plays an important role in palliating symptoms in elderly prostate cancer patients due to progressive local and metastatic disease. Palliative RT is effective in relieving local pelvic symptoms, such as hematuria, pain, and obstructive symptoms. Hindson et al. treated 35 hormonally refractive prostate cancer patients with a median dose of 60 Gy in 20 fractions and noted complete and partial responses in 8.6% and 51.4% of patients, respectively [57].

Palliative RT is also commonly used in

Testicular tumors

Malignant neoplasms of testis have low incidence in the elderly. Overall, seminoma is the commonest type of germ cell tumor encountered. The spermatocytic type, which accounts for only 1% to 2% of seminomas, tends to occur in the elderly. Such tumors are usually confined to the testes and no adjuvant therapy is typically required. However, adjuvant RT has been traditionally employed for stage I classic seminomas. Given the rarity of these tumors in older population, the recommended treatment

Conclusions

There is an imperative need for the acquisition of quality data to formulate optimal treatment guidelines for elderly patients with prostate and other urologic cancers. The medical community should design clinical trials for older patients as well as to include this subgroup of patients in all prospective trials. Future trials should also incorporate measures of quality of care and treatment outcomes, including toxicity relevant to the older population. This would provide valuable information

References (74)

  • B.S. Teh et al.

    Intensity modulated radiation therapy (IMRT) following prostatectomy: More favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2001)
  • D.P. Dearnaley et al.

    Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomized controlled trial

    Lancet Oncol

    (2007)
  • M.J. Zelefsky et al.

    Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer

    J Urol

    (2006)
  • O. Cahlon et al.

    Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes

    Int J Radiat Oncol Biol Phys

    (2006)
  • W. Song et al.

    Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: A radiobiological analysis

    Int J Radiat Oncol Biol Phys

    (2006)
  • A.B. Jani et al.

    Analysis of acute toxicity with the use of transabdominal ultrasonography for prostate positioning during intensity modulated radiotherapy

    Urol

    (2005)
  • A. Nichol et al.

    A phase II trial of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy

    Radiother Oncol

    (2005)
  • P. Kupelian et al.

    Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy

    Int J Radiat Oncol Biol Phys

    (2007)
  • P.A. Kupelian et al.

    Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

    Int J Radiat Oncol Biol Phys

    (2007)
  • J.F. Fowler et al.

    What hypofractionated protocols should be tested for prostate cancer?

    Int J Radiat Oncol Biol Phys

    (2003)
  • E. Miles et al.

    Hypofractionation for prostate cancer: A critical review

    Semin Radiat Oncol

    (2008)
  • C. Vargas et al.

    Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer

    Int J Radiat Oncol Biol Phys

    (2008)
  • J.D. Slater et al.

    Proton therapy for prostate cancer: The initial Loma Linda University experience

    Int J Radiat Oncol Biol Phys

    (2004)
  • E. Steenland et al.

    The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastases study

    Radiother Oncol

    (1999)
  • I. Resche et al.

    A dose-controlled study of 153Sm-ethyleneddiaminetetramethrylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases

    Eur J Cancer

    (1997)
  • K. Foell et al.

    Rare case of classic testicular seminoma in an 86-year-old shows similar proliferation rate as in younger men

    Urology

    (2007)
  • S. Gori et al.

    Germ cell tumors of the testis

    Crit Rev Oncol Hematol

    (2005)
  • C. Visco et al.

    Non-Hodgkin's lymphoma affecting the testis: Is it curable with doxorubicin-based therapy?

    Clin Lymphoma

    (2001)
  • J. Miedler et al.

    Primary testicular lymphoma

    J Urol

    (2007)
  • A. Zouhair et al.

    Outcome and patterns of failure in testicular lymphoma: A multicenter rare cancer network study

    Int J Radiat Oncol Biol Phys

    (2002)
  • L.P. Muren et al.

    Image-guided radiotherapy of bladder cancer: Bladder volume variation and its relation to margins

    Radiother Oncol

    (2007)
  • S. Kotwal et al.

    Similar outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center

    Int J Radiat Oncol Biol Phys

    (2008)
  • B. Kavanagh et al.

    Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases

    Semin Radiat Oncol

    (2006)
  • M. Ozsahin et al.

    Treatment of penile cancer: To cut or not to cut

    Int J Radiat Oncol Biol Phys

    (2006)
  • E. Solsona et al.

    EAU guidelines on penile cancer

    Eur Urol

    (2004)
  • A. Jemal et al.

    Cancer statistics, 2005

    CA Cancer J Clin

    (2005)
  • A. Sandhu et al.

    Radiation therapy for older cancer patients

    Aging Health

    (2006)
  • Cited by (4)

    View full text